Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label extension study of eculizumab in transfusion-dependent hemolytic PNH
2005-000043-28Phase 3Completed
- Sponsor
- Alexion Pharmaceuticals
- Start
- Mar 2005
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of eculizumab in paroxysmal nocturnal hemoglobinuria (PNH), sponsored by Alexion Pharmaceuticals. Primary endpoints: Treatment-emergent adverse events, Clinical laboratory data and 2 more. Started Mar 2005; status: completed.
02
Drugs
eculizumab
03
Conditions
paroxysmal nocturnal hemoglobinuria (PNH)
Beyond the preview
Go deeper on 2005-000043-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-000043-28.